Summary
This 8-K filing from Johnson & Johnson (JNJ) reports on a revised agreement to acquire Guidant Corporation for approximately $21.5 billion in equity value. The original acquisition agreement was entered into in December 2004. This updated deal terms reflect a significant transaction in the medical device sector, with Johnson & Johnson aiming to integrate Guidant's operations into its portfolio. Investors should note the revised purchase price and the structure of the deal, which involves a combination of cash and JNJ common stock. The estimated net acquisition cost is $19 billion, accounting for Guidant's cash on hand at closing. The transaction is subject to Guidant shareholder approval and is expected to close in the first quarter of 2006, representing a key strategic move for Johnson & Johnson to enhance its market presence.
Key Highlights
- 1Johnson & Johnson and Guidant Corporation have entered into a revised agreement for JNJ to acquire Guidant.
- 2The revised acquisition value is approximately $21.5 billion in fully diluted equity value.
- 3The estimated net acquisition cost, after considering Guidant's cash on hand, is approximately $19 billion.
- 4Guidant shareholders will receive $33.25 in cash and 0.493 shares of Johnson & Johnson common stock per Guidant share.
- 5The per-share value to Guidant shareholders, based on November 14, 2005 closing prices, is $63.08.
- 6Both companies' boards of directors have approved the revised agreement.
- 7The transaction is contingent on Guidant shareholder approval and is expected to close in Q1 2006.